ETON Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
37.6M
+54.9%
24.3M
+14.0%
21.3M
-5.2%
22.5M
+18.7%
18.9M
Cost of Revenue
12.2M
+27.8%
9.5M
+16.5%
8.2M
-44.0%
14.6M
+108.5%
7.0M
Gross Profit
25.4M
+72.5%
14.7M
+12.5%
13.1M
+66.8%
7.9M
-34.1%
11.9M
Operating Expenses
12.6M
+2.4%
12.3M
+15.8%
10.6M
+15.4%
9.2M
-31.2%
13.4M
R&D
993.0K
-47.0%
1.9M
+5.3%
1.8M
+60.1%
1.1M
-70.0%
3.7M
SG&A
11.6M
+11.3%
10.4M
+18.0%
8.9M
+9.3%
8.1M
-16.3%
9.7M
Operating Income
12.8M
+430.0%
2.4M
-2.0%
2.5M
+280.8%
-1363000
+7.6%
-1475000
EBITDA
14.2M
+300.0%
3.5M
+1.8%
3.5M
+1083.3%
-354000
+24.7%
-470000
Net Income
11.6M
+645.0%
1.6M
+4.8%
1.5M
+177.0%
-1927000
+25.5%
-2585000
EPS (Basic)
$0.42
+600.0%
$0.06
+0.0%
$0.06
+185.7%
$-0.07
+30.0%
$-0.10
EPS (Diluted)
$0.35
+600.0%
$0.05
-16.7%
$0.06
+185.7%
$-0.07
+30.0%
$-0.10
Shares (Diluted)
32.8M
+3.9%
31.5M
+17.0%
27.0M
+0.2%
26.9M
+0.0%
26.9M
Eton Pharmaceutcials (ETON) โ€” Financials